Regdanvimab - Celltrion
Alternative Names: CT P59; IN 006 - Celltrion/Inhalon Biopharma; IN-006; Regkirona; T-P59Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Celltrion
- Developer Celltrion; Inhalon Biopharma
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in Australia (Inhalation)
- 20 Mar 2024 Pharmacokinetics and adverse events data from a phase I trial in COVID-2019 infections (In volunteers) released by Inhalon Biopharma
- 28 Aug 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in United Kingdom (IV, Infusion)